Kidder Stephen W Bristol Myers Squibb CO Transaction History

Kidder Stephen W

$333 Million
Q3 2024

A detailed history of Kidder Stephen W transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Kidder Stephen W holds 4,600 shares of BMY stock, worth $275,770. This represents 0.07% of its overall portfolio holdings.

Number of Shares

4,600

Previous 5,150 10.68%

Holding current value

$275,770

Previous $213,000 11.74%

% of portfolio

0.07%

Previous 0.07%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$39.66 - $51.75 $21,812 - $28,462	-550 Reduced 10.68%	4,600 $238,000
Q2 2024 Aug 12, 2024	SELL	$40.25 - $52.99 $2,012 - $2,649	-50 Reduced 0.96%	5,150 $213,000
Q1 2024 May 13, 2024	SELL	$47.98 - $54.4 $6,765 - $7,670	-141 Reduced 2.64%	5,200 $281,000
Q4 2023 Feb 13, 2024	SELL	$48.48 - $57.85 $6,787 - $8,099	-140 Reduced 2.55%	5,341 $274,000
Q1 2023 May 10, 2023	SELL	$65.71 - $74.53 $6,570 - $7,453	-100 Reduced 1.79%	5,481 $379,000
Q4 2022 Feb 09, 2023	BUY	$68.48 - $81.09 $382,186 - $452,563	5,581 New	5,581 $401,000
Q1 2019 May 01, 2019	SELL	$45.12 - $53.8 $218,832 - $260,930	-4,850 Closed	0 $0
Q3 2018 Oct 15, 2018	SELL	$55.19 - $62.25 $27,595 - $31,125	-500 Reduced 9.35%	4,850 $301,000
Q2 2018 Jul 30, 2018	SELL	$50.53 - $62.98 $7,579 - $9,447	-150 Reduced 2.73%	5,350 $297,000
Q1 2018 Apr 24, 2018	SELL	$59.92 - $68.98 $65,912 - $75,878	-1,100 Reduced 16.67%	5,500 $347,000
Q4 2017 Feb 02, 2018	BUY	$59.94 - $65.35 $95,904 - $104,559	1,600 Added 32.0%	6,600 $405,000
Q3 2017 Oct 26, 2017	BUY	$55.23 - $63.74 $276,150 - $318,700	5,000	5,000 $318,000

Others Institutions Holding BMY

# of Institutions

2,604

Shares Held

1.47B

Call Options Held

31.5M

Put Options Held

34.9M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $127B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kidder Stephen W, based on Form 13F filings with the SEC.

News

Stay updated on Kidder Stephen W with notifications on news.

Account